David Francisco
Chief Financial Officer at Organogenesis
The 2025 net revenue guidance range continues to assume net revenue from Advanced Wound Care products of between $450,000,000 and $500,000,000 representing a year over year change in the range of a decline of 1% to an increase of 10% net revenues from Surgical and Sports Medicine products of between 30,000,000 and $35,000,000 representing a year over year increase in the range of 6% to 23%. With respect to our profitability and EBITDA guidance, the company now expects GAAP net income in a range of $4,700,000 to $34,000,000 compared to $9,500,000 and $38,800,000 previously, EBITDA in a range of $20,000,000 to $59,600,000 compared to $27,000,000 to $66,600,000 previously non GAAP adjusted net income in the range of $15,300,000 to 44,600,000.0 unchanged versus our prior guidance and adjusted EBITDA in the range of $43,600,000 to $83,200,000 again, unchanged versus our prior guidance. In addition to our formal financial guidance for 2025, we are providing some considerations for modeling purposes. We continue to expect the environment to be very challenging through the first half of twenty twenty five, followed by a significant improvement in our business trends beginning in the third quarter. For modeling purposes, we expect the second quarter revenue in the range of approximately $100,000,000 to $110,000,000 Our profitability guidance for 2025 now assumes gross margin in the range of approximately 78% to 79% compared to seventy six percent to 78% previously GAAP operating expenses up low single digits year over year and excluding noncash intangible amortization of approximately $3,300,000 the nonrecurring FDA payment related to our BLA filing of $4,600,000 and the $6,600,000 write down of assets in Q1, our total non GAAP operating expenses will increase approximately 5% to 7% year over year.